Dendrirx: multi-action topical capsaicin for peripheral nerve pain
Dendrirx is a Health Canada-licensed topical cream designed to alleviate peripheral nerve pain from conditions like diabetic neuropathy and post-herpetic neuralgia. It combines capsaicin with cinnamaldehyde and L-arginine/L-citrulline for enhanced efficacy, targeting both sensory and microvascular contributors to neuropathic symptoms. Market-ready and manufactured following cGMP standards, it offers a localized, non-opioid alternative to systemic therapies.
Overview
Dendrirx is a topical cream specifically formulated to address the complex etiology of peripheral nerve pain, including diabetic neuropathy and post-herpetic neuralgia. Its unique multi-action formulation combines capsaicin, a well-known TRPV1 agonist, with cinnamaldehyde (TRPA1) and L-arginine/L-citrulline to enhance local circulation and warming effects. This combination targets both sensory and microvascular contributors to neuropathic symptoms, offering a non-opioid, non-systemic solution that avoids the side effects associated with oral pain medications.
Technical specifications
Key features:
- Contains capsaicin 0.075%, cinnamaldehyde, and L-arginine/L-citrulline
- TRPV1 and TRPA1 agonists for sensory modulation
- Supports nitric-oxide microcirculatory effects
- cGMP manufactured and Health Canada licensed (NPN 80123181)
- Proven safety profile with no reported adverse effects
- Increases skin temperature and peripheral perfusion
- Reduces pain, tingling, numbness, and swelling with significant efficacy (p<0.01)
Technology readiness level
Dendrirx is at Technology Readiness Level 9, indicating it is commercially available and has been marketed successfully since 2023. The product is ready for further expansion into new markets, with plans to launch under the US OTC Monograph and pursue additional regulatory approvals for broader indications. The evidence base includes over 10,000 units sold with positive real-world outcomes and no adverse event reports.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.